In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials.

ATP Binding Cassette Transporter, Subfamily B / metabolism Administration, Intravenous Animals Cell Differentiation Female Humans Injections, Intramuscular Male Mesenchymal Stem Cell Transplantation / adverse effects Mesenchymal Stem Cells / cytology Mice, Inbred NOD Quality Control Skin / cytology Tissue Distribution
ABCB5 GMP MSC biodistribution persistence safety stem cells stromal cells toxicity tumorigenicity

Journal

Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309

Informations de publication

Date de publication:
05 2019
Historique:
received: 23 11 2018
revised: 19 12 2018
accepted: 26 12 2018
pubmed: 18 3 2019
medline: 15 4 2020
entrez: 18 3 2019
Statut: ppublish

Résumé

Human dermal ABCB5-expressing mesenchymal stromal cells (ABCB5 To support the development of ABCB5 (i) Subcutaneous application of 1 × 10 The present preclinical in vivo data demonstrate the local and systemic safety and tolerability of a novel advanced-therapy medicinal product based on human skin-derived ABCB5

Sections du résumé

BACKGROUND AIMS
Human dermal ABCB5-expressing mesenchymal stromal cells (ABCB5
METHODS
To support the development of ABCB5
RESULTS
(i) Subcutaneous application of 1 × 10
DISCUSSION
The present preclinical in vivo data demonstrate the local and systemic safety and tolerability of a novel advanced-therapy medicinal product based on human skin-derived ABCB5

Identifiants

DOI: 10.1016/j.jcyt.2018.12.005 PMID: 30878384 PMC: PMC6513723
pubmed: 30878384
pii: S1465-3249(18)30723-0
doi: 10.1016/j.jcyt.2018.12.005
pmc: PMC6513723
mid: NIHMS1027450
pii:
doi:

Substances chimiques

ABCB5 protein, human 0
ATP Binding Cassette Transporter, Subfamily B 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

546-560

Subventions

Organisme : BLRD VA
ID : I01 BX000516
Pays : United States
Organisme : RRD VA
ID : I01 RX000989
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY025794
Pays : United States
Organisme : NEI NIH HHS
ID : R24 EY028767
Pays : United States

Informations de copyright

Copyright © 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.

Références

Cell Med. 2016 Oct 03;9(3):87-102
pubmed: 28713639
Int J Med Sci. 2018 Jan 1;15(1):36-45
pubmed: 29333086
Toxicol Pathol. 2009 Aug;37(5):606-16
pubmed: 19478280
Blood. 2010 Feb 25;115(8):1549-53
pubmed: 20032501
Stem Cells. 2006 Apr;24(4):1095-103
pubmed: 16282438
Stem Cells Int. 2013;2013:678063
pubmed: 24222773
Cell Rep. 2015 Sep 8;12(10):1564-74
pubmed: 26321644
Oncotarget. 2016 Nov 22;7(47):77416-77429
pubmed: 27764806
Stem Cells Transl Med. 2018 Sep;7(9):651-663
pubmed: 30070053
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Toxicol Pathol. 2015 Jan;43(1):115-25
pubmed: 25476796
Stem Cell Res Ther. 2016 Jan 11;7:7
pubmed: 26753925
Cancer Res. 2009 Jul 1;69(13):5331-9
pubmed: 19509230
Cell Stem Cell. 2009 Mar 6;4(3):206-16
pubmed: 19265660
Stem Cells Transl Med. 2017 Sep;6(9):1786-1794
pubmed: 28722289
Stem Cells. 2007 Feb;25(2):371-9
pubmed: 17038675
PLoS One. 2012;7(10):e47559
pubmed: 23133515
Clin Transl Med. 2014 Jul 10;3:21
pubmed: 25097724
J Immunol. 2010 May 15;184(10):5885-94
pubmed: 20382885
World J Stem Cells. 2015 Mar 26;7(2):408-17
pubmed: 25815124
Ann Rheum Dis. 2017 Jan;76(1):196-202
pubmed: 27269294
Cytotherapy. 2013 Jul;15(7):753-9
pubmed: 23602595
J Immunol. 2005 May 15;174(10):6477-89
pubmed: 15879151
Immunol Cell Biol. 2013 Jan;91(1):40-51
pubmed: 23207278
Stem Cell Rev Rep. 2013 Feb;9(1):65-79
pubmed: 22237468
Sci Rep. 2013;3:2298
pubmed: 23892388
J Transl Med. 2011 Mar 22;9:29
pubmed: 21418664
J Stem Cells Regen Med. 2015 Dec 31;11(2):34-43
pubmed: 27330253
Cytotherapy. 2017 Dec;19(12):1438-1446
pubmed: 29122516
Cytotherapy. 2017 Jan;19(1):61-74
pubmed: 27836573
Stem Cells Int. 2013;2013:732742
pubmed: 24000286
Stem Cells. 2016 Sep;34(9):2393-406
pubmed: 27299700
Lab Invest. 2017 Oct;97(10):1218-1224
pubmed: 28892093
Cancer Res. 2007 Oct 1;67(19):9142-9
pubmed: 17909019
Cytotherapy. 2017 Dec;19(12):1351-1382
pubmed: 28964742
J Biol Chem. 2003 Nov 21;278(47):47156-65
pubmed: 12960149
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3290-4
pubmed: 1373493

Auteurs

Nils Tappenbeck (N)

RHEACELL GmbH & Co. KG, Heidelberg, Germany.

Hannes M Schröder (HM)

TICEBA GmbH, Heidelberg, Germany.

Elke Niebergall-Roth (E)

TICEBA GmbH, Heidelberg, Germany.

Fathema Hassinger (F)

RHEACELL GmbH & Co. KG, Heidelberg, Germany.

Ulf Dehio (U)

RHEACELL GmbH & Co. KG, Heidelberg, Germany.

Kathrin Dieter (K)

RHEACELL GmbH & Co. KG, Heidelberg, Germany.

Korinna Kraft (K)

RHEACELL GmbH & Co. KG, Heidelberg, Germany.

Andreas Kerstan (A)

Department of Dermatology, Venereology, and Allergology, University Hospital, Würzburg, Germany.

Jasmina Esterlechner (J)

TICEBA GmbH, Heidelberg, Germany.

Natasha Y Frank (NY)

Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts, USA; Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Transplant Research Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.

Karin Scharffetter-Kochanek (K)

Department of Dermatology and Allergic Diseases, University Hospital, Ulm, Germany.

George F Murphy (GF)

Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Dennis P Orgill (DP)

Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Joachim Beck (J)

Aesthetic Quartier Heidelberg GmbH, Heidelberg, Germany.

Markus H Frank (MH)

Transplant Research Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA; School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.

Christoph Ganss (C)

RHEACELL GmbH & Co. KG, Heidelberg, Germany; TICEBA GmbH, Heidelberg, Germany.

Mark A Kluth (MA)

RHEACELL GmbH & Co. KG, Heidelberg, Germany; TICEBA GmbH, Heidelberg, Germany. Electronic address: andreas.kluth@ticeba.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Pompes ioniques › Transporteurs d'anions › Transporteurs d'anions organiques › Transporteurs d'anions organiques ATP-dépendants › Sous-famille B de transporteurs à cassette liant l'ATP › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie intraveineuse › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Eucaryotes › Animaux › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Différenciation cellulaire › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Injections › Injections musculaires › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches mésenchymateuses › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches multipotentes › Cellules souches mésenchymateuses › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée NOD › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Contrôle de qualité › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Système tégumentaire › Peau › In vivo safety profile and biodistribution of...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › In vivo safety profile and biodistribution of...